je.st
news
Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
2014-06-14 19:01:32| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION Real-world study presented at the American Diabetes Association 74th Scientific Sessions Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more
Tags: and
type
show
data
Category:Biotechnology and Pharmaceuticals